Dr. Arun Singh on an Early-Stage Trial of Immunotherapy for Advanced Sarcomas
Arun Singh, MD, assistant professor, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), discusses a phase Ib/II trial of immunotherapy for patients with advanced sarcoma.
Arun Singh, MD, assistant professor, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), discusses a phase Ib/II trial of immunotherapy for patients with advanced sarcoma.
This trial examined adoptive cellular therapy with autologous lymphocytes genetically modified to express an NY-ESO-1-specific T-cell receptor and dendritic cell vaccination with or without ipilimumab (Yervoy). Patients who had failed standard therapies were evaluated.
In this trial, seven patients were evaluated and two responded. Of those responders, one had 50-60 metastases in their lungs and most shrunk or were completely eliminated. The other patient experienced a complete response that has lasted 15 months.
Because ipilimumab has been added and nivolumab (Opdivo) will be added, Singh says, researchers want to determine which patients will respond best while experiencing minimal side effects.
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More
